TipRanks
AIxCrypto Holdings (DE:7R90)
FRANKFURT:7R90

AIxCrypto Holdings (7R90) Price & Analysis

2 Followers

7R90 Stock Chart & Stats

€2.62
€0.00(0.00%)
At close: 4:00 PM EDT
€2.62
€0.00(0.00%)

Bulls Say, Bears Say

Bulls Say
Robotics Pivot Reached Initial CommercializationThe pivot from digital assets toward physical AI robotics has moved beyond planning into a live paid deployment. An initial commercial order provides early validation for RoboShare, while the proposed ten-city rollout could create a clearer operating model if repeat demand and unit economics develop.
Asset-light Marketplace ModelUsing existing and third-party robot capacity may let RoboShare expand supply with less upfront capital than owning a large fleet. This asset-light structure can improve scalability and preserve financial flexibility, provided the marketplace attracts repeat customers and supports attractive per-order economics.
Low Leverage And Sequential Cost DisciplineMinimal debt reduces fixed financing pressure and leaves the company less exposed to interest costs than a highly leveraged growth business. Recent sequential expense reductions also show management can tighten spending, although continued execution is needed for this discipline to translate into sustainability.
Bears Say
Absent Revenue And Worsening LossesThe company has not established a durable revenue base, while losses have widened from $6.3M in 2024 to $17.0M in 2025 and $22.9M TTM. Persistent negative operating earnings and gross profit indicate substantial uncertainty around the viability of the current business model.
Severe Liquidity Pressure And Cash BurnVery limited cash relative to ongoing operating needs creates substantial funding risk as RoboShare is still being commercialized. Management acknowledged going-concern doubt and said pilot pace is gated by available capital, which could restrict investment, delay expansion, or require additional financing.
Digital-asset Losses And Capital Allocation RiskThe digital-asset treasury has suffered a roughly $5.22M unrealized decline from cost, adding volatility to reported results and weakening asset support. The $12M Faraday Future investment was also material relative to cash on hand, increasing the importance of disciplined capital allocation during the robotics transition.

AIxCrypto Holdings News

7R90 FAQ

What was AIxCrypto Holdings’s price range in the past 12 months?
AIxCrypto Holdings lowest stock price was €2.63 and its highest was €5.65 in the past 12 months.
    What is AIxCrypto Holdings’s market cap?
    AIxCrypto Holdings’s market cap is €20.07M.
      When is AIxCrypto Holdings’s upcoming earnings report date?
      AIxCrypto Holdings’s upcoming earnings report date is Apr 01, 2027 which is in 190 days.
        How were AIxCrypto Holdings’s earnings last quarter?
        AIxCrypto Holdings released its earnings results on Aug 07, 2026. The company reported -€0.18 earnings per share for the quarter.
          Is AIxCrypto Holdings overvalued?
          According to Wall Street analysts AIxCrypto Holdings’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does AIxCrypto Holdings pay dividends?
            AIxCrypto Holdings does not currently pay dividends.
            What is AIxCrypto Holdings’s EPS estimate?
            AIxCrypto Holdings’s EPS estimate for its next earnings report is not yet available.
            How many shares outstanding does AIxCrypto Holdings have?
            AIxCrypto Holdings has 21,108,885 shares outstanding.
              What happened to AIxCrypto Holdings’s price movement after its last earnings report?
              AIxCrypto Holdings reported an EPS of -€0.18 in its last earnings report. Following the earnings report the stock price went same 0%.
                Which hedge fund is a major shareholder of AIxCrypto Holdings?
                Currently, no hedge funds are holding shares in DE:7R90
                What is the TipRanks Smart Score and how is it calculated?
                Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

                  Company Description

                  AIxCrypto Holdings

                  AIxCrypto Holdings, Inc. is a clinical-stage biopharmaceutical company committed to discovering and developing innovative treatments for both adult and pediatric oncology. Its leading investigational therapeutic, QN-302, is a small molecule G-quadruplexes (G4)-selective transcription inhibitor currently progressing through Phase I clinical trials for pancreatic cancer and a range of other solid tumors. The firm is also advancing Pan-RAS, a preclinical-stage program targeting advanced solid tumors. Founded in 1996 and headquartered in Carlsbad, California, the company rebranded from Qualigen Therapeutics, Inc. to AIxCrypto Holdings, Inc. in November 2025.

                  AIxCrypto Holdings (7R90) Earnings & Revenues

                  7R90 Company Deck

                  7R90 Earnings Call

                  Q2 2026
                  0:00 / 0:00
                  Earnings Call Sentiment|Negative
                  The call highlighted meaningful operational progress: the public launch of the RoboShare marketplace, an LA pilot targeted to begin in August, an asset-light second-life strategy for robots, sequential cost reductions and internal AI Agent testing. However, the company faces material near-term challenges: constrained liquidity with only $577K cash, large unrealized digital-asset losses, significant YTD cash burn and no material recognized revenue yet (revenues contingent on pilot execution). Year-over-year operating expense increases and a larger quarterly net loss versus the prior year further weigh on the outlook. While management has taken steps to reduce expenses and retain share count, the combination of limited cash runway and deferred strategic initiatives creates significant execution risk.View all DE:7R90 earnings summaries
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Eterna Therapeutics
                  Xenetic Biosciences
                  Genprex
                  IN8bio
                  Popular Stocks